Company intelligence / Profile preview
Adaptimmune Therapeutics
Philadelphia, Pennsylvania, United Statesadaptimmune.com ↗
- Ownership
- Public · ADAPY
- Employees
- ~506
- Development stage
- Other
01
Overview
Adaptimmune developed the first FDA-approved T cell receptor (TCR) therapy for cancer, with afamitresgene autoleucel (Tecelra) for metastatic synovial sarcoma, showing a 43% overall response rate in trials. Letetresgene autoleucel (lete-cel) has received FDA breakthrough therapy designation for myxoid/round cell liposarcoma and synovial sarcoma.
- Therapeutic areas
- OncologyHematology
- Modalities
- T cell receptor engineered T cell therapyCell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
48 assets47 more assets in the full pipeline.
03
Partnerships
AGC BiologicsUS WorldMeds
04
Financials
- Market cap
- $5M
- Total revenue
- $5.9M
- Enterprise value
- $27.7M
Beyond the preview
Go deeper on Adaptimmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adaptimmune Therapeutics.